• Species Reactivity

  Human

• Specificity

  Detects human IL‑28A/IFN‑ lambda 2 in direct ELISAs. In direct ELISAs, 83% cross-reactivity with recombinant human (rh) IL-28B/IFN-lambda 3 and no cross-reactivity with recombinant mouse IL-28B/IFN-lambda 3 or rhIL-29/IFN-l1 is observed.

• Source

  Monoclonal Mouse IgG    ₁ Clone # 248526

• Purification

  Protein A or G purified from hybridoma culture supernatant

• Immunogen

  Mouse myeloma cell line NS0-derived recombinant human IL‑28A/IFN‑ lambda 2    
  Val26-Val200    
  Accession # Q8IZJ0

• Formulation

  Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.

• Endotoxin Level

  <0.10 EU per 1 μg of the antibody by the LAL method.  

• Label

  Unconjugated

Applications

• 
  

  Recommended    
  Concentration

  Sample

• Neutralization

  Measured by its ability to neutralize IL‑28A/IFN‑ lambda 2 inhibition of EMCV-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line. Sheppard, P.     et al. (2003) Nat. Immunol.     4:63. The Neutralization Dose (ND    ₅₀) is typically 0.25-1.0 µg/mL in the presence of 0.1 µg/mL Recombinant Human IL‑28A/IFN‑ lambda 2.

Please Note: Optimal dilutions should be determined by each laboratory for each application.  are available in the Technical Information section on our website.

Data Examples

Preparation and Storage

• Reconstitution

  Reconstitute at 0.5 mg/mL in sterile PBS.

• Shipping

  The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

• Stability & Storage

  Use a manual defrost freezer and avoid repeated freeze-thaw cycles.    

• 12 months from date of receipt, -20 to -70 °C as supplied.

• 1 month, 2 to 8 °C under sterile conditions after reconstitution.

• 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IL-28A/IFN-lambda 2

IL-28A, IL-28B, and IL-29, also named interferon-lambda 2 (IFN-lambda 2), IFN-lambda 3, and IFN-lambda 1, respectively, are class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11‑13% aa sequence identity) and type I IFN family (15‑19% aa sequence identity) (1‑3). The expression of IL-28A, B, and IL-29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and
up‑regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL‑10 receptor  beta
(IL‑10 R beta ) and a novel IL‑28 receptor alpha (IL‑28 R alpha, also known as IFN-lambda R1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation. The phosphorylated STAT1 and STAT2 complex with IFN-regulatory factor 9 (IRF-9) to form the IFN-stimulated regulatory factor 3 (ISGF-3) transcription factor complex that is translocated to the nucleus. ISGF-3 binds to the IFN-stimulated response element (ISRE) present in the regulatory regions of the target genes. Human IL-28A cDNA encodes a 200 amino acid (aa) residue precursor protein with a 25 aa signal peptide. It shares 94% and 67% aa sequence identity with human IL-28B and human IL-29, respectively.

• References:

1. Vilcek, J. (2003) Nature Immunol. 4:8.

2. Sheppard, P. et al. (2003) Nature Immunol. 4:63.

3. Kotenko, S.V. et al. (2003) Nature Immunol. 4:69.

• Long Name:

  Interleukin 28A

• Entrez Gene IDs:

  282616 (Human)

• Alternate Names:

  interleukin-28A; IFN-lambda 2; IL28A; IL-28A; interferon, lambda 2